Summary of the Conference Call on the Health Supplement CDMO Industry Industry Overview - The health supplement market in China is the second largest globally, with significant growth potential due to low penetration rates, approximately 1/4 to 1/5 of that in Europe and the US [1][4] - The largest segment is vitamin dietary supplements (EDS), accounting for about 60% of the market, with a noticeable trend towards functional foods [1][4] - The dual-track regulatory policy (registration + filing) has lowered entry barriers and accelerated product launches while enhancing regulatory oversight [1][5] Key Trends and Insights - Online channels have significantly impacted the health supplement market, achieving a penetration rate of around 60%, the highest globally, which has disrupted traditional offline channels [1][9] - Emerging brands are leveraging online platforms to target specific demographics, leading to a decline in traditional dietary supplement market share [1][9] - The concentration of brands and contract manufacturing in the health supplement industry is low, below 20%, with new online brands further dispersing market concentration [1][8] Regulatory Impact - The introduction of the dual-track system in 2016 has streamlined the approval process for new products, allowing for quicker market entry while increasing regulatory scrutiny to eliminate non-compliant products [5][7] - The 2019 Tianjin Qianjin incident led to stricter internal control mechanisms and a comprehensive industry cleanup, enhancing the overall transparency and standardization of the market [5][6] Consumer Demand and Behavior - Increasing income and health awareness among Chinese consumers are driving demand for health supplements, with a shift from serious health products to functional foods [6][12] - The traditional dietary supplement consumption patterns are evolving, with younger demographics becoming the primary consumers, influenced by the rise of online shopping [6][9] Company-Specific Insights Xianle Health - Xianle Health, a leading player in the health supplement CDMO sector, has achieved continuous revenue growth through international expansion and product innovation, despite profit fluctuations due to industry and global factors [3][13] - The acquisition of the US-based BF company has temporarily impacted profits but is expected to become a long-term growth driver [3][18] - Collaborations with new consumer brands have improved domestic revenue, with a notable partnership with brands like Dongfang Zhenxuan and Yang Men Dian [3][17] Baihe Co. - Baihe Co. has recently acquired New Zealand's Auri Company, which is expected to contribute to revenue growth [21] - The company has shown strong performance in the functional beverage sector, adapting well to new consumer demands despite being less focused on large client customization compared to Xianle [21] Future Outlook - The health supplement CDMO industry in China has substantial growth potential, with a current penetration rate of about 10%, lower than that of Europe and Japan (15%-20%) [12] - The high online penetration rate suggests a promising future for contract manufacturing, with expectations of increased demand driven by the rise of online sales channels [12][20] - Xianle plans to enhance cooperation with new consumer clients and expand into Southeast Asia through cross-border e-commerce and new factory setups [20]

Investment Rating - The investment rating for the company is "Buy" and is maintained [6] Core Views - The company reported a total revenue of 2.042 billion yuan for H1 2025, representing a year-on-year increase of 2.57%. The net profit attributable to shareholders was 161 million yuan, up 4.3% year-on-year, while the net profit excluding non-recurring items was 159 million yuan, an increase of 3.25% year-on-year [2][4] - In Q2 2025, the company achieved a total revenue of 1.087 billion yuan, reflecting a year-on-year growth of 4.66%. The net profit attributable to shareholders was approximately 92.5 million yuan, a 1.13% increase year-on-year, and the net profit excluding non-recurring items was about 94.4 million yuan, up 5.46% year-on-year [2][4] - The company experienced varied performance across regions, with revenue in China declining by 1.63% to 818 million yuan, while revenue in the Americas grew by 4.26% to 760 million yuan, and Europe saw a significant increase of 21.96% to 359 million yuan [10] - The company's gross profit margin improved by 1.14 percentage points to 33.18% in H1 2025, while the net profit margin increased by 0.13 percentage points to 7.89% [10] - The company is expected to benefit from the aging population and changes in consumer habits post-public health events, leading to a stable upward trend in the health supplement industry [10] - Forecasted net profits for the company are 353 million yuan, 455 million yuan, and 535 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 1.15, 1.48, and 1.74 yuan, and PE ratios of 21, 16, and 14 times [10]

Investment Dynamics - The Better Meat Co. announced the completion of a $31 million Series A funding round, led by Future Ventures and Resilience Reserve, with participation from other investors [3] - The company, founded in 2018, operates on a B2B model, providing plant-based proteins to food service suppliers and meat processors, enhancing product quality and sustainability [3] Acquisition Dynamics - China Mengniu Dairy is considering selling approximately 20% of its ice cream brand Aice, seeking a valuation of around $1 billion, focusing on Southeast Asian markets [6] - Mengniu's move is seen as a strategy to generate cash flow and refocus on high-margin liquid milk and cheese products [6] Brand Dynamics - Budweiser announced a $15 million investment in its St. Louis brewery to create and maintain manufacturing jobs, part of a larger $300 million investment plan [10] - This investment aligns with Budweiser's strategy to focus on high-margin local craft and ready-to-drink channels amid a saturated global beer market [10] Company Developments - Aland Health Holding is considering selling its shares, with an estimated valuation exceeding $1.5 billion, marking a potential significant merger in China's health supplement industry [8] - Meituan's international delivery brand Keeta has launched in Qatar, with plans to expand further into the Middle East and South America [12] Personnel Changes - Hershey has appointed Natalie Rothman as Chief Human Resources Officer, indicating a shift from a product-driven to an operations efficiency-driven approach [23] - Valentino announced Riccardo Bellini as the new CEO, tasked with inspiring employee engagement and accelerating the brand's creative restructuring [26] - Target's current CEO Brian Cornell will be succeeded by Michael Fiddelke, an internal candidate, which may facilitate a smoother transition amid recent sales challenges [28]

• 麦角硫因价格构成中，品牌端到消费端利润最高，毛利率可达 70%- 90%。掌握高纯度原料并降低成本是核心竞争力。企业通过提高纯度降低 成本，使终端价格更具竞争力。 • 生物合成技术降低麦角硫因价格，两条链纯度定价约 8,500-9,500 元/公 斤，四条链 10 万元以上。华睿和景山生物口碑较好，毛利率至少 50%。 发酵规模扩大后，蛋白类产品成本将显著下降。 保健品代工行业是否存在技术壁垒？ 麦角硫因产业链解构专家电话会 20250518 摘要 • 国内麦角硫因生产受限，依赖跨境电商，但假货问题突出。品牌方、原料 方和渠道方需联合行动，提高消费者认知，确保产品功效，并引导消费者 通过专业渠道购买，以应对市场乱象。 • 保健品代工行业存在技术壁垒，头部代工厂如仙乐和百合通过包埋技术和 调香提升产品价值。行业内企业对法规持观望态度，头部企业通过升级产 品规格和联合推广提高消费者认知。 • 麦角硫因产品毛利率高，集中在生产端，高纯度是核心竞争力。景山生物 等公司纯度达 99.99%，影响代工厂利润空间。化学合成可能引入重金属， 质检和工艺质检至关重要。 • 抗衰市场热度增加，麦角硫因作为天然抗氧化剂，直接作 ...